Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
주식 순위 #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
주가
$8.74
마지막 동기화: 2026-08-28
시가총액
$699.74M
변동 (1일)
-4.85%
변동 (1년)
-2.29%
국가
US
거래 BridgeBio Oncology Therapeutics Inc. (BBOT)

카테고리

BridgeBio Oncology Therapeutics Inc. (BBOT)의 EPS
2026 기준 EPS TTM: 0
BridgeBio Oncology Therapeutics Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
BridgeBio Oncology Therapeutics Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH